Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis
Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis
复制标题
DOI：
10.1136/bjo.87.4.423
复制
发表时间：
2003-04-01
影响因子：
4.1
通讯作者：
Stübiger, N
中科院分区：
文献类型：
--
作者：
Kötter, I;Zierhut, M;Stübiger, N
Background: Behcet's disease is a multisystem vasculitis of unknown origin. Standard treatment mainly comprises systemic immunosuppressive agents. Ocular involvement, mostly posterior uveitis with retinal vasculitis, leads to blindness in 20-50% of the involved eyes within 5 years. The efficacy of interferon alfa-2a was studied in patients with sight threatening posterior uveitis or retinal vasculitis.Methods: 50 patients were included in this open, non-randomised, uncontrolled prospective study. Recombinant human interferon alfa-2a (rhIFNalpha-2a) was applied at a dose of 6 million units subcutaneously daily. Dose reduction was performed according to a decision tree until discontinuation. Disease activity was evaluated every 2 weeks by the Behcets disease activity scoring system and the uveitis scoring system.Results: Response rate of the ocular manifestations was 92% (three non-responder, one incomplete response). Mean visual acuity rose significantly from 0.56 to 0.84 at week 24 (p
